Production (Stage)
ReShape Lifesciences Inc.
RSLS
$4.76
-$0.18-3.64%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 8.01M | 8.18M | 8.05M | 8.34M | 8.68M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.01M | 8.18M | 8.05M | 8.34M | 8.68M |
| Cost of Revenue | 2.95M | 2.60M | 2.62M | 2.85M | 3.13M |
| Gross Profit | 5.06M | 5.58M | 5.43M | 5.49M | 5.55M |
| SG&A Expenses | 9.92M | 11.48M | 12.53M | 14.36M | 17.87M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.67M | 16.10M | 17.31M | 19.55M | 23.32M |
| Operating Income | -6.67M | -7.92M | -9.26M | -11.22M | -14.64M |
| Income Before Tax | -7.09M | -7.00M | -8.96M | -10.87M | -11.34M |
| Income Tax Expenses | 40.00K | 66.00K | 63.00K | 52.00K | 52.00K |
| Earnings from Continuing Operations | -7.13 | -7.07 | -9.02 | -10.92 | -11.39 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.13M | -7.07M | -9.02M | -10.92M | -11.39M |
| EBIT | -6.67M | -7.92M | -9.26M | -11.22M | -14.64M |
| EBITDA | -6.65M | -7.90M | -9.19M | -11.11M | -14.48M |
| EPS Basic | -366.64 | -464.85 | -387.17 | -295.48 | -159.92 |
| Normalized Basic EPS | -242.40 | -302.86 | -254.49 | -182.31 | -98.12 |
| EPS Diluted | -366.64 | -464.85 | -387.17 | -295.48 | -159.92 |
| Normalized Diluted EPS | -242.40 | -302.86 | -254.49 | -182.31 | -98.12 |
| Average Basic Shares Outstanding | 82.50K | 64.60K | 44.20K | 26.80K | 10.60K |
| Average Diluted Shares Outstanding | 82.50K | 64.60K | 44.20K | 26.80K | 10.60K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |